Sharing data for cancer research
Biblio
] PET imaging of hypoxia using [18F]HX4: a phase I trial. European Journal of Nuclear Medicine and Molecular Imaging. 2010;37(9):1663 - 1668. doi:10.1007/s00259-010-1437-x.
PET imaging of hypoxia using [18F]HX4: a phase I trial. European Journal of Nuclear Medicine and Molecular Imaging. 2010;37(9):1663 - 1668. doi:10.1007/s00259-010-1437-x.
PET imaging of hypoxia using [18F]HX4: a phase I trial. European Journal of Nuclear Medicine and Molecular Imaging. 2010;37(9):1663 - 1668. doi:10.1007/s00259-010-1437-x.
PET imaging of hypoxia using [18F]HX4: a phase I trial. European Journal of Nuclear Medicine and Molecular Imaging. 2010;37(9):1663 - 1668. doi:10.1007/s00259-010-1437-x.
Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging. Proceedings of the National Academy of Sciences. 2011;108(35):14620 - 14625. doi:10.1073/pnas.1102526108.
A semiautomatic CT-based ensemble segmentation of lung tumors: comparison with oncologists' delineations and with the surgical specimen. Radiother Oncol. 2012;105(2):167-73. doi:10.1016/j.radonc.2012.09.023.
A semiautomatic CT-based ensemble segmentation of lung tumors: comparison with oncologists' delineations and with the surgical specimen. Radiother Oncol. 2012;105(2):167-73. doi:10.1016/j.radonc.2012.09.023.
. Benefits of a clinical data warehouse with data mining tools to collect data for a radiotherapy trial. Radiotherapy and Oncology. 2013;108(1):174 - 179. doi:10.1016/j.radonc.2012.09.019.
Cardiac comorbidity is an independent risk factor for radiation-induced lung toxicity in lung cancer patients. Radiotherapy and Oncology. 2013;109(1):100 - 106. doi:10.1016/j.radonc.2013.08.035.
Cardiac comorbidity is an independent risk factor for radiation-induced lung toxicity in lung cancer patients. Radiotherapy and Oncology. 2013;109(1):100 - 106. doi:10.1016/j.radonc.2013.08.035.
Cardiac comorbidity is an independent risk factor for radiation-induced lung toxicity in lung cancer patients. Radiotherapy and Oncology. 2013;109(1):100 - 106. doi:10.1016/j.radonc.2013.08.035.
Prognostic value of metabolic metrics extracted from baseline positron emission tomography images in non-small cell lung cancer. Acta Oncol. 2013;52(7):1398-404. doi:10.3109/0284186X.2013.812795.
Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006. doi:10.1038/ncomms5006.
. International data-sharing for radiotherapy research: an open-source based infrastructure for multicentric clinical data mining. Radiother Oncol. 2014;110(2):370-374. doi:10.1016/j.radonc.2013.11.001.
Data from: Development and Evaluation of an Online Three-Level Proton vs Photon Decision Support Prototype for Head and Neck Cancer - Comparison of Dose, Toxicity and Cost-Effectiveness. 2015. doi:10.17195/candat.2015.10.5.
PRODECIS-HNC-results.xlsx (43.25 KB)
PRODECIS-HNC-Figure-2.png (47.07 KB)
PRODECIS-HNC-results.xlsx (43.25 KB) PRODECIS-HNC-Figure-2.png (47.07 KB)
Data from: MMP2 small immuno protein antibody uptake in xenograft tumors is associated with MMP2 activity. 2015. doi:10.17195/candat.2015.10.6.
Panth_MMP2-activity-vs-uptake.csv (2.03 KB) Panth_MMP2-analysis.csv (6.1 KB)
Panth_MMP2-representative-images.rar (570.44 KB)
Panth_MMP2-activity-vs-uptake.csv (2.03 KB) Panth_MMP2-analysis.csv (6.1 KB) Panth_MMP2-representative-images.rar (570.44 KB) A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients. Int J Radiat Oncol Biol Phys. 2015;92(4):935-44. doi:10.1016/j.ijrobp.2015.02.048.
A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients. Int J Radiat Oncol Biol Phys. 2015;92(4):935-44. doi:10.1016/j.ijrobp.2015.02.048.
A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients. Int J Radiat Oncol Biol Phys. 2015;92(4):935-44. doi:10.1016/j.ijrobp.2015.02.048.
A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients. Int J Radiat Oncol Biol Phys. 2015;92(4):935-44. doi:10.1016/j.ijrobp.2015.02.048.
Data from: Nitroglycerin in non-small cell lung cancer: does it impact tumor hypoxia and tumor perfusion? A window-of-opportunity clinical trial. 2016. doi:10.17195/candat.2016.07.2.
2017-08-28 Reymen - Nitro database HX-4 DCECT clean.zip (20.3 KB)
2017-08-28 Reymen - Nitro database HX-4 DCECT clean.zip (20.3 KB) Data from: Developing and validating a survival prediction model for NSCLC patients through distributed learning across three countries. 2017. doi:10.17195/candat.2017.02.2. Jochems-2017-MaastroDataUnbinned.csv (62.76 KB)
Jochems-2017-MaastroDataUnbinned.csv (62.76 KB) Data from: Developing and validating a survival prediction model for NSCLC patients through distributed learning across three countries. 2017. doi:10.17195/candat.2017.02.2. Jochems-2017-MaastroDataUnbinned.csv (62.76 KB)
Jochems-2017-MaastroDataUnbinned.csv (62.76 KB)